Grant Hutchins, MD
Gastroenterology · Omaha, NENPI 1629091988
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.2%), food and beverage and other — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Integer Holdings Corporation at 50.0% of the total. Reporting peaked in 2023 at $3,954 and has fallen 59.6% since, to $1,597 in 2025.
Across 417 payments — averaging $34.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integer Holdings Corporation$7K
- AbbVie$2K
- Johnson & Johnson$796
- Gilead$690
- Takeda Pharmaceuticals U.S.A., Inc.$538
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
- plus $3K from 25 others
What the payments were for
- Consulting fees$7,29450%
- Food & beverage$7,20050%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integer Holdings Corporation | 6 | $7,263 |
| AbbVie(2 entities) | 111 | $1,623 |
| Johnson & Johnson | 56 | $796 |
| Gilead | 34 | $690 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $538 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $406 |
| Madrigal Pharmaceuticals | 19 | $351 |
| Bristol Myers Squibb | 23 | $342 |
| Aimmune Therapeutics, Inc. | 2 | $330 |
| QOL Medical, LLC | 19 | $317 |
| Sanofi | 14 | $294 |
| Nestle Healthcare Nutrition Inc. | 3 | $221 |
| Amgen | 10 | $181 |
| Intercept Pharmaceuticals, Inc. | 10 | $162 |
| Regeneron Healthcare Solutions, Inc. | 8 | $147 |
| Merck | 8 | $135 |
| Ipsen Biopharmaceuticals, Inc | 5 | $131 |
| Ardelyx, Inc. | 6 | $101 |
| Ironwood Pharmaceuticals, Inc | 6 | $99 |
| Lilly USA, LLC | 4 | $83 |
| Pfizer | 5 | $71 |
| Phathom Pharmaceuticals, Inc. | 6 | $48 |
| Boston Scientific | 1 | $40 |
| Sandoz | 2 | $39 |
| Boehringer Ingelheim | 1 | $29 |
| Redhill Biopharma Inc. | 1 | $17 |
| Welch Allyn | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Organon | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| UCB, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,523 in reported general payments places this provider in the 85th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $331,455 |
| XeljanzTofacitinib Citrate | 13 | $70,703 |
| CreonLipase/Protease/Amylase | 22 | $55,269 |
| LinzessLinaclotide | 26 | $24,233 |
| MotegrityPrucalopride Succinate | 33 | $18,045 |
| AprisoMesalamine | 16 | $6,705 |
| NexiumEsomeprazole Magnesium | 13 | $3,684 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 151 | $3,201 |
| Sucralfate | 44 | $3,108 |
| Mesalamine ErMesalamine | 43 | $2,831 |
| Omeprazole | 231 | $2,749 |
| Colestipol Hcl | 54 | $2,635 |
| Ursodiol | 19 | $2,560 |
| Pantoprazole Sodium | 153 | $1,864 |
| Colesevelam Hcl | 13 | $1,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $796 | $331,45512 claims |
| AbbVieCreon, Linzess | $1,623 | $79,50248 claims |
| PfizerXeljanz | $71 | $70,70313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $538 | $18,04533 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso | $406 | $6,70516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Trevor PearsonOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.